Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer. Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the objective response rate to sorafenib tosylate (sorafenib) in children with relapsed or refractory rhabdomyosarcoma, Wilms tumor, hepatocellular carcinoma (HCC), or papillary thyroid carcinoma (PTC).

SECONDARY OBJECTIVES:

I. To further define and describe the toxicities of sorafenib administered on an oral, twice-daily continuous schedule.

II. To further characterize the pharmacokinetics of sorafenib in children with refractory cancer.

III. To estimate the progression-free survival on sorafenib for rhabdomyosarcoma, Wilms tumor, and hepatocellular carcinoma and compare to a group of patients enrolled on selected closed Phase II studies of Children Oncology Group (COG).

IV. To assess the biologic activity of sorafenib on vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor-2 (VEGFR-2) in peripheral blood samples. (Exploratory) V. To evaluate the presence of BRAF mutations and RET/PTC rearrangements in patients with PTC. (Exploratory)

OUTLINE: This is a multicenter study. Patients are stratified according to diagnosis (rhabdomyosarcoma vs Wilms tumor vs hepatocellular carcinoma vs papillary thyroid carcinoma).

Patients receive sorafenib tosylate orally (PO) twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.

Patients undergo blood sample collection at baseline and periodically during study for pharmacokinetic studies, and VEGF and VEGFR-2 analysis by ELISA. Previously collected formalin-fixed paraffin-embedded tissue samples, from patients with papillary thyroid carcinoma, are also analyzed for BRAF mutation and RET/PTC rearrangements by PCR.

After completion of study treatment, patients are followed up for up to 5 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01502410
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Completed
Phase Phase 2
Start date January 2012
Completion date June 2014

See also
  Status Clinical Trial Phase
Completed NCT01441154 - Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
Active, not recruiting NCT04544111 - PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Phase 2
Recruiting NCT03469011 - A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. Phase 1
Recruiting NCT05752669 - Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
Recruiting NCT04076514 - The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
Completed NCT06439745 - More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
Active, not recruiting NCT01723202 - Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Phase 2
Recruiting NCT05500508 - Oral AMXT 1501 Dicaprate in Combination With IV DFMO Phase 1/Phase 2
Active, not recruiting NCT02568267 - Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Phase 2
Unknown status NCT02140476 - Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy N/A
Recruiting NCT06286631 - Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
Completed NCT06325787 - Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma N/A
Terminated NCT01974284 - Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma N/A
Active, not recruiting NCT00984191 - Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid N/A
Active, not recruiting NCT04731467 - A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05668962 - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Phase 2
Completed NCT02178345 - Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
Not yet recruiting NCT06133374 - Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
Completed NCT03470259 - Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging Phase 1
Active, not recruiting NCT04129411 - Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation N/A